RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

INTRODUCTION: Novel rearranged in transfection (RET)-specific tyrosine kinase inhibitors (TKIs) such as selpercatinib (LOXO-292) have shown unprecedented efficacy in tumors positive for RET fusions or mutations, notably RET fusion-positive NSCLC and RET-mutated medullary thyroid cancer (MTC). Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Solomon, Benjamin J., Tan, Lavinia, Lin, Jessica J., Wong, Stephen Q., Hollizeck, Sebastian, Ebata, Kevin, Tuch, Brian B., Yoda, Satoshi, Gainor, Justin F., Sequist, Lecia V., Oxnard, Geoffrey R., Gautschi, Oliver, Drilon, Alexander, Subbiah, Vivek, Khoo, Christine, Zhu, Edward Y., Nguyen, Michele, Henry, Dahlia, Condroski, Kevin R., Kolakowski, Gabrielle R., Gomez, Eliana, Ballard, Joshua, Metcalf, Andrew T., Blake, James F., Dawson, Sarah-Jane, Blosser, Wayne, Stancato, Louis F., Brandhuber, Barbara J., Andrews, Steve, Robinson, Bruce G., Rothenberg, S. Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430178/
https://www.ncbi.nlm.nih.gov/pubmed/31988000
http://dx.doi.org/10.1016/j.jtho.2020.01.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430178/
https://www.ncbi.nlm.nih.gov/pubmed/31988000
http://dx.doi.org/10.1016/j.jtho.2020.01.006

Ejemplares similares